Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1Condition 2aCondition 2bCondition 2cCondition 3aCondition 3b
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale92 days10CMO:0000037hematocrit44%0.98033.1MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) 107814DHD/K12/TRb cells (1.5 X 10E6) sanguinarine (5 mg/kg/d)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale92 days10CMO:0000037hematocrit51%1.04363.3MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107813DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale71 days10CMO:0000037hematocrit52.7%0.69572.2MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) 107812DHD/K12/TRb cells (1.5 X 10E6) sanguinarine (5 mg/kg/d)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale71 days10CMO:0000037hematocrit52.3%0.94873.0MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) 107811DHD/K12/TRb cells (1.5 X 10E6) vehicle control condition (1 ml)
3097Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.erythrocyte quantityred blood cell count, hematocritRS:0001789BDIX/CrCrlmale56 days20CMO:0000037hematocrit47.6%0.02240.1MMO:0000214hematocrit analysis0.0DHD/K12/TRb cells (1.5 X 10E6) 107810DHD/K12/TRb cells (1.5 X 10E6)
2541Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.erythrocyte quantityRS:0003240MWF/ZtmRrrcmale126 days10CMO:0000037hematocrit51%0.31621.0MMO:0000214hematocrit analysis0.0enalapril (50 mg/l) (for 60 days)100914enalapril (50 mg/l) (for 60 days)
2541Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.erythrocyte quantityRS:0003240MWF/ZtmRrrcmale126 days8CMO:0000037hematocrit50%0.35361.0MMO:0000214hematocrit analysis0.0control condition100913control condition
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit42%1.03.0MMO:0000214hematocrit analysis0.0PA IV 50mg/kg490dayscontrolled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) 100444controlled enalapril content drinking water (50 mg/l) (for 497 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days8CMO:0000037hematocrit44%1.02.8284MMO:0000214hematocrit analysis0.0PA IV 50mg/kg490dayspuromycin aminonucleoside (50 mg/kg) 100443puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit44%1.03.0MMO:0000214hematocrit analysis0.00.9% sodium chloride solution (3 ml) 1004420.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days8CMO:0000037hematocrit43%1.02.8284MMO:0000214hematocrit analysis0.0PA IV 50mg/kgcontrolled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) 100441controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit43%1.03.0MMO:0000214hematocrit analysis0.0PA IV 50mg/kgpuromycin aminonucleoside (50 mg/kg) 100440puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days8CMO:0000037hematocrit45%1.02.8284MMO:0000214hematocrit analysis0.00.9% sodium chloride solution (3 ml) 1004390.9% sodium chloride solution (3 ml)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days5CMO:0000037hematocrit35%1.02.2361MMO:0000214hematocrit analysis0.0PA IV 50mg/kg23dayscontrolled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) 100438controlled enalapril content drinking water (50 mg/l) (for 30 days)puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days7CMO:0000037hematocrit39%1.02.6458MMO:0000214hematocrit analysis0.0PA IV 50mg/kg23dayspuromycin aminonucleoside (50 mg/kg) 100437puromycin aminonucleoside (50 mg/kg)
2479Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.erythrocyte quantityRS:0000742WKYmale0 days9CMO:0000037hematocrit41%1.03.0MMO:0000214hematocrit analysis0.00.9% sodium chloride solution (3 ml) 1004360.9% sodium chloride solution (3 ml)
2561Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.erythrocyte quantityRS:0000592MWmale0 days8CMO:0000037hematocrit36%1.02.8284MMO:0000214hematocrit analysis0.05/6 nephrectomy28daysnephrectomy (for 28 days) then reserpine (5 mg/l) (for 21 days) and hydralazine (80 mg/l) (for 21 days) and hydrochlorothiazide (25 mg/l) (for 21 days)100988nephrectomy (for 28 days)reserpine (5 mg/l) (for 21 days)hydralazine (80 mg/l) (for 21 days)hydrochlorothiazide (25 mg/l) (for 21 days)
2561Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.erythrocyte quantityRS:0000592MWmale0 days8CMO:0000037hematocrit38%1.02.8284MMO:0000214hematocrit analysis0.05/6 nephrectomy28daysnephrectomy (for 28 days) then enalapril (50 mg/l) (for 21 days)100987nephrectomy (for 28 days)enalapril (50 mg/l) (for 21 days)
2561Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.erythrocyte quantityRS:0000592MWmale0 days8CMO:0000037hematocrit40%1.02.8284MMO:0000214hematocrit analysis0.05/6 nephrectomy28daysnephrectomy (for 28 days) then control condition100986nephrectomy (for 28 days)control condition
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.erythrocyte quantityRS:0003075SS-Nppbem2Mcwi-/-male252 days6CMO:0000037hematocrit50.6%1.33.1843MMO:0000214hematocrit analysis0.0control condition (for 252 days)99737control condition (for 252 days)
2319Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.erythrocyte quantityRS:0003076SS-Nppbem2Mcwi+/+male252 days6CMO:0000037hematocrit52.3%1.84.4091MMO:0000214hematocrit analysis0.0control condition (for 252 days)99736control condition (for 252 days)
2802Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.erythrocyte quantityRS:0000817SS/Jrmale63 days10CMO:0000037hematocrit47%2.26.957MMO:0000214hematocrit analysis0.0controlled sodium content diet (8 %) (for 35 days) then anesthetic/analgesic103269controlled sodium content diet (8 %) (for 35 days)anesthetic/analgesic
2802Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.erythrocyte quantityRS:0000817SS/Jrmale63 days15CMO:0000037hematocrit48.8%0.51.9365MMO:0000214hematocrit analysis0.0controlled sodium content diet (0.3 %) (for 35 days) then anesthetic/analgesic103268controlled sodium content diet (0.3 %) (for 35 days)anesthetic/analgesic
2802Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.erythrocyte quantityRS:0000786SR/Jrmale63 days13CMO:0000037hematocrit43.5%0.51.8028MMO:0000214hematocrit analysis0.0controlled sodium content diet (8 %) (for 35 days) then anesthetic/analgesic103267controlled sodium content diet (8 %) (for 35 days)anesthetic/analgesic
2802Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.erythrocyte quantityRS:0000786SR/Jrmale63 days16CMO:0000037hematocrit45.8%0.41.6MMO:0000214hematocrit analysis0.0controlled sodium content diet (0.3 %) (for 35 days) then anesthetic/analgesic103266controlled sodium content diet (0.3 %) (for 35 days)anesthetic/analgesic
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days16CMO:0000037hematocrit44.5%0.62.4MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days)99979unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days16CMO:0000037hematocrit45.8%0.52.0MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days)99978unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) enalapril (10 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days17CMO:0000037hematocrit45.6%0.31.2369MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days)99977unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) bosentan (100 mg/kg/d) (for 154 days)
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days17CMO:0000037hematocrit44.8%0.62.4739MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition99976unilateral nephrectomy (for 28 days)streptozotocin (35 mg/kg) vehicle control condition
2378Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.erythrocyte quantityRS:0000742WKYmale0 days11CMO:0000037hematocrit45.2%1.44.6433MMO:0000214hematocrit analysis0.0unx168daysunilateral nephrectomy (for 28 days) then vehicle control condition99975unilateral nephrectomy (for 28 days)vehicle control condition
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days10CMO:0000037hematocrit46.7%0.82.5298MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days) then captopril (30 mg/kg/d) 100850right nephrectomy (for 56 days)captopril (30 mg/kg/d)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days10CMO:0000037hematocrit48.4%1.44.4272MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days) then reserpine (5 mg/l) and hydralazine (80 mg/l) and hydrochlorothiazide (25 mg/l) 100849right nephrectomy (for 56 days)reserpine (5 mg/l) hydralazine (80 mg/l) hydrochlorothiazide (25 mg/l)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days6CMO:0000037hematocrit44.8%0.61.4697MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days)100848right nephrectomy (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days5CMO:0000037hematocrit41%1.94.2485MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days) then angiotensin II receptor antagonist (80 mg/l) (for 56 days)100861right nephrectomy (for 112 days)angiotensin II receptor antagonist (80 mg/l) (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days7CMO:0000037hematocrit40.5%2.15.5561MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days) then angiotensin II receptor antagonist (20 mg/l) (for 56 days)100860right nephrectomy (for 112 days)angiotensin II receptor antagonist (20 mg/l) (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days10CMO:0000037hematocrit44%1.03.1623MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days) then lisinopril (10 mg/kg/d) (for 56 days)100859right nephrectomy (for 112 days)lisinopril (10 mg/kg/d) (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days9CMO:0000037hematocrit44.6%1.03.0MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days) then enalapril (20 mg/kg/d) (for 56 days)100858right nephrectomy (for 112 days)enalapril (20 mg/kg/d) (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days10CMO:0000037hematocrit45.3%1.13.4785MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days) then captopril (30 mg/kg/d) (for 56 days)100857right nephrectomy (for 112 days)captopril (30 mg/kg/d) (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days10CMO:0000037hematocrit45.8%0.72.2136MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days) then reserpine (5 mg/l) (for 56 days) and hydralazine (80 mg/l) (for 56 days) and hydrochlorothiazide (25 mg/l) (for 56 days)100856right nephrectomy (for 112 days)reserpine (5 mg/l) (for 56 days)hydralazine (80 mg/l) (for 56 days)hydrochlorothiazide (25 mg/l) (for 56 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days6CMO:0000037hematocrit41.2%1.74.1641MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy112daysright nephrectomy (for 112 days)100855right nephrectomy (for 112 days)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days5CMO:0000037hematocrit45%1.12.4597MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days) then angiotensin II receptor antagonist (80 mg/l) 100854right nephrectomy (for 56 days)angiotensin II receptor antagonist (80 mg/l)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days7CMO:0000037hematocrit44.5%2.46.3498MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days) then angiotensin II receptor antagonist (20 mg/l) 100853right nephrectomy (for 56 days)angiotensin II receptor antagonist (20 mg/l)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days10CMO:0000037hematocrit44%1.03.1623MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days) then lisinopril (10 mg/kg/d) 100852right nephrectomy (for 56 days)lisinopril (10 mg/kg/d)
2523Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.erythrocyte quantityRS:0000592MWmale0 days9CMO:0000037hematocrit47.3%0.92.7MMO:0000214hematocrit analysis0.0~5/6 to 7/8 nephrectomy56daysright nephrectomy (for 56 days) then enalapril (20 mg/kg/d) 100851right nephrectomy (for 56 days)enalapril (20 mg/kg/d)
151Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.erythrocyte quantityRS:0000811SS/JrHsdMcwifemale92 days to 89 days15CMO:0000037hematocrit38.8%1.45.4222MMO:0000214hematocrit analysis0.0controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days)69482controlled sodium content diet (0.4 %) (for 35 days)controlled sodium content diet (0.1 %) (for 35 days)controlled sodium content diet (8 %) (between 22 and 24 days)
151Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.erythrocyte quantityRS:0000145BN/NHsdMcwifemale92 days to 89 days15CMO:0000037hematocrit41.6%0.41.5492MMO:0000214hematocrit analysis0.0controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days)69481controlled sodium content diet (0.4 %) (for 35 days)controlled sodium content diet (0.1 %) (for 35 days)controlled sodium content diet (8 %) (between 22 and 24 days)
102Zhao L et al., 2001, Circulation, 103(3), 442-7erythrocyte quantityRS:0001072WKY/NCrukmale105 days28CMO:0000037hematocritmedian71%MMO:0000214hematocrit analysis0air oxygen content (10 %) (for 21 days)66134air oxygen content (10 %) (for 21 days)
102Zhao L et al., 2001, Circulation, 103(3), 442-7erythrocyte quantityRS:0001072WKY/NCrukmale105 days12CMO:0000037hematocritmedian45%MMO:0000214hematocrit analysis0control condition66133control condition
102Zhao L et al., 2001, Circulation, 103(3), 442-7erythrocyte quantityRS:0000363F344/NHsdmale105 days23CMO:0000037hematocritmedian70%MMO:0000214hematocrit analysis0air oxygen content (10 %) (for 21 days)66132air oxygen content (10 %) (for 21 days)
102Zhao L et al., 2001, Circulation, 103(3), 442-7erythrocyte quantityRS:0000363F344/NHsdmale105 days12CMO:0000037hematocritmedian46%MMO:0000214hematocrit analysis0control condition66131control condition
567Yao H, et al., Physiol Genomics. 2007 Feb 27;.erythrocyte quantityRS:0001433SHRSP.WKY-(D1Wox29-D1Arb21)/Izmmale84 days to 70 days7CMO:0000037hematocrit43%0.3781.0MMO:0000214hematocrit analysis0control condition65526control condition
567Yao H, et al., Physiol Genomics. 2007 Feb 27;.erythrocyte quantityRS:0001433SHRSP.WKY-(D1Wox29-D1Arb21)/Izmmale150 days9CMO:0000037hematocrit45%0.66672.0MMO:0000214hematocrit analysis0control condition65525control condition
567Yao H, et al., Physiol Genomics. 2007 Feb 27;.erythrocyte quantityRS:0000770SHRSP/Izmmale150 days7CMO:0000037hematocrit44%1.13393.0MMO:0000214hematocrit analysis0control condition65524control condition
567Yao H, et al., Physiol Genomics. 2007 Feb 27;.erythrocyte quantityRS:0000770SHRSP/Izmmale84 days to 70 days8CMO:0000037hematocrit42%0.70712.0MMO:0000214hematocrit analysis0control condition65523control condition